{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"13"}],"units":"Participants"}],"description":"Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for intermittent dosing schedule (MWF weekly).\n\nA 3-parameter version of a Bayesian logistic regression model with overdose control (Babb, Rogatko, and Zacks 1998) was used during the dose escalation phase for dose level selection and determination of the MTD.","groups":[{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG000","title":"Arm 2, Group X (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG001","title":"Arm 2, Group X (45 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG002","title":"Arm 2, Group X (60 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG003","title":"Arm 2, Group X (80 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.","id":"OG004","title":"Arm 2, Group Y (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.","id":"OG005","title":"Arm 2, Group Y (45 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.","id":"OG006","title":"Arm 2, Group Y (60 mg) - MTD"}],"paramType":"NUMBER","populationDescription":"MTD-determining population: All patients from the safety population who were in the dose escalation phase of the study, and who received panobinostat for ≥ 9 full doses in arm 1 during cycle 1 and completed all required safety evaluations; or who received panobinostat.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28-day treamtent cycle)","title":"Number of Participants DLT in Arm 2 in Dose Escalation Phase","type":"PRIMARY","unitOfMeasure":"Participants"}